|
GlobalDrugsDirect.com is your trusted licensed Canadian Pharmacy!
|
Accupril
Information
QUINAPRIL is an ACE inhibitor used to treat high blood pressure and to help treat heart failure. QUINAPRIL comes as brown tablets containing 5, 10, 20 or 40 mg of the active ingredient quinapril. The 5 mg tablets are oval, the 10 mg tablets are triangular, the 20 mg tablets are round and the 40 mg tablets are oval. The 5 mg tablet is stamped with the strength on both sides and the 10, 20 and 40 mg tablets are stamped with the strength on one side only. The 5, 10 and 20 mg tablets have a line dividing them in half on both sides, while the 40 mg tablet is unlined. Each strength of Quinapril is supplied in bottles of 90 tablets.
The active ingredient, quinapril, belongs to a group of medicines called angiotensin converting enzyme (ACE) inhibitors. ACE inhibitors work by widening blood vessels in the body, which can reduce the pressure in the vessels.
Accupril
Directions
Quinapril is usually taken once or twice a day. You will start on a low dose which may be increased if necessary by your doctor until you are taking exactly the amount you need. Quinapril should only be taken by mouth. Try to take the tablets at the same time/s every day, either with or without food.
If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. Do not take two doses at the same time.
If you accidentally take too much Accupro, tell your doctor at once. If you can't do this, go to the nearest hospital accident and emergency department. Take along any tablets that are left, the container and the label so that the hospital staff can easily tell what medicine you have taken.
Accupril
Side Effects
QUINAPRIL is an ACE inhibitor used to treat high blood pressure and to help treat heart failure. QUINAPRIL comes as brown tablets containing 5, 10, 20 or 40 mg of the active ingredient quinapril. The 5 mg tablets are oval, the 10 mg tablets are triangular, the 20 mg tablets are round and the 40 mg tablets are oval. The 5 mg tablet is stamped with the strength on both sides and the 10, 20 and 40 mg tablets are stamped with the strength on one side only. The 5, 10 and 20 mg tablets have a line dividing them in half on both sides, while the 40 mg tablet is unlined. Each strength of Quinapril is supplied in bottles of 90 tablets.
The active ingredient, quinapril, belongs to a group of medicines called angiotensin converting enzyme (ACE) inhibitors. ACE inhibitors work by widening blood vessels in the body, which can reduce the pressure in the vessels.
Accupril
Precautions
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensinaldosterone
system, treatment with ACE inhibitors, including quinapril, may be associated with oliguria and/or progressive azotemia and rarely acute renal failure and/or death. In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine have been observed in some patients following ACE inhibitor therapy. These increases were almost always reversible upon discontinuation of the ACE inhibitor and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy. Some patients with hypertension or heart failure with no apparent preexisting renal vascular
disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when quinapril has been given concomitantly with a diuretic. This is more likely to occur in patients with preexisting renal impairment. Dosage reduction and/or discontinuation of
any diuretic and/or quinapril may be required.
Evaluation of patients with hypertension or heart failure should always include assessment of renal function.
Hyperkalemia and potassium-sparing diuretics: In clinical trials, hyperkalemia (serum potassium ≥5.8 mmol/L) occurred in approximately 2% of patients receiving quinapril. In most cases, elevated serum potassium levels were isolated values which resolved despite continued therapy. Less than 0.1% of patients discontinued therapy due to hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassiumcontaining
salt substitutes, which should be used cautiously, if at all, with quinapril.
Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent non-productive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough.
Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these
consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has
been limited to the first trimester. These patients should be asked to report pregnancies to their
physicians as soon as possible.
The generic alternative is not manufactured by the company that makes the brand product.
|